A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Clinical trial NCT03332017 · COMPLETED

Trial details

NCT number: NCT03332017
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

Start date: 2017-11-14
Primary completion: 2021-10-08
Enrollment: 217

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.